Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own...
22 insider purchases on record · latest filing 2026-03-09.
Insiders have also filed 202 sale transactions at ARVN.